SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference.

Wahren, B; Biswas, P; Borggren, M; Coleman, A; Da Costa, K; De Haes, W; Dieltjens, T; Dispinseri, S; Grupping, K; Hallengärd, D; et al. Wahren, B; Biswas, P; Borggren, M; Coleman, A; Da Costa, K; De Haes, W; Dieltjens, T; Dispinseri, S; Grupping, K; Hallengärd, D; Hornig, J; Klein, K; Mainetti, L; Palma, P; Reudelsterz, M; Seifried, J; Selhorst, P; Sköld, A; Uchtenhagen, H; van Gils, MJ; Weber, C; Shattock, R; Scarlatti, G (2010) Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conference. JOURNAL OF TRANSLATIONAL MEDICINE, 8 (72). ISSN 1479-5876 https://doi.org/10.1186/1479-5876-8-72
SGUL Authors: Shattock, Robin John

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (306kB) | Preview

Abstract

EUROPRISE is a Network of Excellence sponsored from 2007 to 2011 by the European Commission within the 6th Framework Program. The Network encompasses a wide portfolio of activities ranging from an integrated research program in the field of HIV vaccines and microbicides to training, dissemination and advocacy. The research program covers the whole pipeline of vaccine and microbicide development from discovery to early clinical trials. The Network is composed of 58 partners representing more than 65 institutions from 13 European countries; it also includes three major pharmaceutical companies (GlaxoSmithKline, Novartis and Sanofi-Pasteur) involved in HIV microbicide and vaccine research. The Network displays a dedicated and informative web page: http://www.europrise.org. Finally, a distinguishing trait of EUROPRISE is its PhD School of students from across Europe, a unique example in the world of science aimed at spreading excellence through training. EUROPRISE held its second annual conference in Budapest in November, 2009. The conference had 143 participants and their presentations covered aspects of vaccine and microbicide research, development and discovery. Since training is a major task of the Network, the students of the EUROPRISE PhD program summarized certain presentations and their view of the conference in this paper.

Item Type: Article
Additional Information: PubMed ID: 20659333 ©2010 Wahren et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: AIDS Vaccines, Adaptive Immunity, Animals, Anti-Infective Agents, Clinical Trials as Topic, Disease Susceptibility, Drug Design, Europe, HIV Infections, HIV-1, Humans, Immunity, Mucosal, Mice, Neutralization Tests, Science & Technology, Life Sciences & Biomedicine, Medicine, Research & Experimental, Research & Experimental Medicine, SIMIAN IMMUNODEFICIENCY VIRUS, CD4(+) T-LYMPHOCYTES, DENDRITIC CELLS, HUMORAL IMMUNITY, INFECTION, ANTIBODIES, RESPONSES, IMMUNIZATION, STRATEGIES, DISEASE
Journal or Publication Title: JOURNAL OF TRANSLATIONAL MEDICINE
ISSN: 1479-5876
Related URLs:
Dates:
DateEvent
26 July 2010Published
Web of Science ID: WOS:000282449400001
Download EPMC Full text (PDF)
Download EPMC Full text (HTML)
URI: https://openaccess.sgul.ac.uk/id/eprint/145
Publisher's version: https://doi.org/10.1186/1479-5876-8-72

Actions (login required)

Edit Item Edit Item